Skip to content

Genetically Engineered Mouse Colitis Models for Preclinical Drug Development

Genetically engineered mouse colitis models are increasing the flexibility and predictive validity of preclinical colitis models in inflammatory bowel disease (IBD) research. These powerful tools are increasingly supplementing or replacing traditional chemically induced models (e.g. DSS- or TNBS-induced colitis), and offer important translational and mechanistic insights in IBD drug development.

Colitis Models for Preclinical Drug Development

This webinar will introduce the genetically engineered mouse colitis models available from Taconic Biosciences, including Rag2 knockouts (for adoptive T cell transfer and anti-CD40-induced colitis), Mdr1a knockouts, and Il10 knockouts. For each, we will review disease mechanisms, pathological features, endpoints, and critical considerations when planning to add these to your research repertoire.

You can expect to learn:

  • The characteristics and uses of Rag2, Mdr1a, and Il10 knockouts in colitis research; the power of each and how to choose amongst these
  • How genetically engineered mouse colitis models compare to standard chemically induced models
  • The role of the microbiome in colitis models
  • Tips and tricks for getting these models to work in your institution

Dr. Philip Dubé

Senior Scientist | Taconic Biosciences

Dr. Philip Dubé is a Senior Scientist with Taconic Biosciences focusing on microbiome and immunology applications in mouse research models. He earned his Ph.D. from the University of Toronto and completed postdoctoral fellowships in inflammatory bowel disease research at Vanderbilt University and Children’s Hospital Los Angeles. Philip’s areas of expertise include mouse models for inflammatory and metabolic diseases, oncology and immuno-oncology.

© 2022 Taconic Biosciences, Inc. All rights reserved.